Free Trial

Lexicon Pharmaceuticals (LXRX) News Today

Lexicon Pharmaceuticals logo
$0.57 +0.01 (+2.55%)
As of 05/20/2025 04:00 PM Eastern

LXRX Latest News

Q2 Earnings Estimate for LXRX Issued By Leerink Partnrs
What is HC Wainwright's Estimate for LXRX Q2 Earnings?
Lexicon Pharmaceuticals, Inc. stock logo
Schonfeld Strategic Advisors LLC Has $5.58 Million Position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)
Schonfeld Strategic Advisors LLC increased its holdings in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) by 301.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 7,558,621 shares of the biophar
Lexicon Pharmaceuticals, Inc. stock logo
Boothbay Fund Management LLC Purchases Shares of 480,822 Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)
Boothbay Fund Management LLC acquired a new position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 480,822 shares of the biopharmaceutical company's stock,
Lexicon Pharmaceuticals, Inc. stock logo
Nantahala Capital Management LLC Acquires 4,300,000 Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)
Nantahala Capital Management LLC grew its holdings in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) by 186.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,604,150 shares of the b
Lexicon Pharmaceuticals, Inc. stock logo
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Given Consensus Recommendation of "Hold" by Analysts
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) has earned a consensus recommendation of "Hold" from the five brokerages that are covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and two have assigned a buy recomm
Lexicon Pharmaceuticals, Inc. stock logo
Lexicon Pharmaceuticals (LXRX) to Post Quarterly Earnings on Thursday
Lexicon Pharmaceuticals (NASDAQ:LXRX) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 1. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-1-lexicon-pharmaceuticals-inc-stock/)
Lexicon Pharmaceuticals, Inc. stock logo
Lexicon Pharmaceuticals (NASDAQ:LXRX) Now Covered by Analysts at StockNews.com
StockNews.com assumed coverage on Lexicon Pharmaceuticals in a research note on Monday. They issued a "sell" rating on the stock.
Lexicon Pharmaceuticals, Inc. stock logo
Lexicon Pharmaceuticals (NASDAQ:LXRX) Coverage Initiated at StockNews.com
StockNews.com assumed coverage on shares of Lexicon Pharmaceuticals in a report on Sunday. They set a "sell" rating for the company.
Lexicon Pharmaceuticals, Inc. stock logo
StockNews.com Begins Coverage on Lexicon Pharmaceuticals (NASDAQ:LXRX)
StockNews.com started coverage on Lexicon Pharmaceuticals in a research report on Saturday. They issued a "sell" rating for the company.
Lexicon Pharmaceuticals, Inc. stock logo
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Short Interest Update
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) was the target of a large drop in short interest in the month of March. As of March 15th, there was short interest totalling 39,260,000 shares, a drop of 17.3% from the February 28th total of 47,460,000 shares. Currently, 17.1% of the company's shares are sold short. Based on an average daily trading volume, of 6,260,000 shares, the days-to-cover ratio is currently 6.3 days.
Lexicon Pharmaceuticals, Inc. stock logo
Lexicon Pharmaceuticals' (LXRX) Buy Rating Reaffirmed at HC Wainwright
HC Wainwright reaffirmed a "buy" rating and set a $4.00 target price on shares of Lexicon Pharmaceuticals in a research report on Friday.
Lexicon Pharmaceuticals, Inc. stock logo
Lexicon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:LXRX)
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) saw unusually large options trading on Friday. Stock traders bought 2,504 call options on the company. This represents an increase of 61% compared to the average volume of 1,558 call options.
Lexicon Pharmaceuticals, Inc. stock logo
Stock Traders Purchase Large Volume of Lexicon Pharmaceuticals Call Options (NASDAQ:LXRX)
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) was the target of some unusual options trading activity on Friday. Stock traders acquired 2,504 call options on the company. This represents an increase of 61% compared to the typical volume of 1,558 call options.
Lexicon stock soars on Novo Nordisk licensing deal
Lexicon Pharmaceuticals, Inc. stock logo
Lexicon Pharmaceuticals (NASDAQ:LXRX) Coverage Initiated by Analysts at StockNews.com
StockNews.com assumed coverage on Lexicon Pharmaceuticals in a research report on Thursday. They issued a "sell" rating for the company.
Lexicon Pharmaceuticals, Inc. stock logo
What is HC Wainwright's Estimate for LXRX Q1 Earnings?
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) - HC Wainwright issued their Q1 2025 EPS estimates for shares of Lexicon Pharmaceuticals in a report issued on Friday, March 7th. HC Wainwright analyst J. Pantginis anticipates that the biopharmaceutical company will post earnings per shar
Lexicon Pharmaceuticals, Inc. stock logo
Equities Analysts Issue Forecasts for LXRX Q1 Earnings
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 EPS estimates for Lexicon Pharmaceuticals in a report issued on Friday, March 7th. HC Wainwright analyst J. Pantginis anticipates that the biopharmaceutical company will post earn
Lexicon Pharmaceuticals, Inc. stock logo
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Given Consensus Recommendation of "Hold" by Brokerages
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) has been assigned a consensus recommendation of "Hold" from the five brokerages that are currently covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating and two have issued a b
Lexicon Pharmaceuticals, Inc. stock logo
Lexicon Pharmaceuticals (NASDAQ:LXRX) Price Target Cut to $6.00 by Analysts at Piper Sandler
Piper Sandler cut their price objective on shares of Lexicon Pharmaceuticals from $10.00 to $6.00 and set an "overweight" rating on the stock in a research note on Friday.
Lexicon Pharmaceuticals, Inc. stock logo
Lexicon Pharmaceuticals (NASDAQ:LXRX) Issues Earnings Results, Beats Expectations By $0.02 EPS
Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.11) by $0.02. Lexicon Pharmaceuticals had a negative net margin of 4,109.41% and a negative return on equity of 107.38%.
Get Lexicon Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter.

LXRX Media Mentions By Week

LXRX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

LXRX
News Sentiment

0.63

0.65

Average
Medical
News Sentiment

LXRX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

LXRX Articles
This Week

15

4

LXRX Articles
Average Week

Get Lexicon Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:LXRX) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners